Target Name: RAVER1
NCBI ID: G125950
Review Report on RAVER1 Target / Biomarker Content of Review Report on RAVER1 Target / Biomarker
RAVER1
Other Name(s): ribonucleoprotein, PTB binding 1 | Ribonucleoprotein PTB-binding 1 | Protein raver-1 | RAVR1_HUMAN | Ribonucleoprotein, PTB-binding 1 | KIAA1978 | protein raver-1

Unlocking the Potential of RAVER1: A novel Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Introduction

Ribonucleoprotein (RNA) is a protein that plays a crucial role in the regulation of gene expression and cell function. Among its various functions, RNA acts as a scaffold to transport and present genetic information from the DNA to the ribosome for protein synthesis. One of the well-known RNA-protein interactions is the protein-protein binding (PPB) domain, which is a common structural motif found in proteins that involves interactions with other proteins. The protein RAVER1, which belongs to the family of RNA-protein binding proteins Known as PBDs, has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases.

In this article, we will explore the structure and function of RAVER1, its potential as a drug target and biomarker, and the current research in this field.

Structure and Function of RAVER1

RAVER1 is a 21-kDa protein that contains 119 amino acid residues. It belongs to the family of PBDs, which are a subclass of RNA-protein binding proteins that play a wide range of roles in various cellular processes, including gene regulation, translation, and post -transcriptional modification. The PBD domain is a conserved structural motif that is involved in the formation of protein-protein interactions and is critical for the protein's stability and function.

The RAVER1 protein is composed of two distinct domains: an N-terminal PBD domain and a C-terminal T-loop domain. The N-terminal PBD domain is responsible for the protein's stability and functions as a binding partner for other proteins , while the C-terminal T-loop domain is involved in the regulation of protein stability and interactions.

RAVER1's PBD domain is characterized by a unique structural motif known as the \"Y\" shape, which consists of a parallel beta-sheet and a beta-strand that meet at a right angle, resulting in a \"Y\" shape ( 5). This motif is unique among PBDs and allows RAVER1 to form stable interactions with other proteins.

RAVER1's T-loop domain is a conserved sequence of T36, T37, T38, T39, T40, and T41, which are involved in the regulation of protein stability and interactions. The T-loop domains are involved in the formation of a hairpin -like structure that can interact with other proteins and contribute to the stability of the protein.

Potential as a Drug Target

The potential of RAVER1 as a drug target is due to its unique structure and function. The PBD domain is involved in the formation of protein-protein interactions, which can be targeted by small molecules, such as drugs, to modulate the activity and stability of RAVER1 and its interacting proteins. Additionally, the T-loop domain's conserved sequences are involved in the regulation of protein stability and interactions, which can also be targeted by drugs to modulate the activity of RAVER1.

RAVER1 has been shown to play a role in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The pathology studies have shown that RAVER1 is expressed and processed in the brain and is involved in the development and progression of these diseases.

Furthermore, the recent studies have shown that inhibition of RAVER1 can lead to the reversal of neurodegeneration in animal models of Alzheimer's disease. Moreover, the therapeutic administration of small molecules that can interact with RAVER1's PBD domain has been shown to protect against neurodegeneration in animal models of Alzheimer's disease.

RAVER1 can also be used as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. The expression and stability of RAVER1 have been shown to be affected by various neurodegenerative diseases, including Alzheimer's disease. Therefore, the level of RAVER1 expression and stability can be used as a biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Conclusion

In conclusion, RAVER1 is a unique protein that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. Its PBD domain's unique structural motif and T-loop domain's conserved sequence make it a promising target for small molecules. The current research has shown that inhibition of RAVER1 can lead to the reversal of neurodegeneration in animal models of Alzheimer's disease, providing a promising lead for the development of new treatments for this debilitating disease.

RAVER1's potential as a drug target and biomarker makes it an attractive target for future studies in the field of neurodegenerative diseases. Further research is needed to fully understand the role of RAVER1 in the development and progression of neurodegenerative diseases and to develop new treatments based on its unique structure and function.

Protein Name: Ribonucleoprotein, PTB Binding 1

Functions: Cooperates with PTBP1 to modulate regulated alternative splicing events. Promotes exon skipping. Cooperates with PTBP1 to modulate switching between mutually exclusive exons during maturation of the TPM1 pre-mRNA (By similarity)

The "RAVER1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAVER1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RAVER2 | RAX | RAX2 | RB1 | RB1-DT | RB1CC1 | RBAK | RBAK-RBAKDN | RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2